• Rathan M. Subramaniam
  • J. M. Davison
  • D. S. Surasi
  • Gregory Russo
  • P. J. Peller
Part of the Medical Radiology book series (MEDRAD)


FDG PET/CT has become the standard-of care for staging, therapy assessment and follow-up of patients with lung cancers. It improves the staging, provides a road map for selective invasive mediastinal nodal biopsy and surgical planning (especially contrast-enhanced PET/CT) and accurately identifies distant metastasis. It improves the tumor delineation for radiation therapy planning by identifying tumor from atelectasis and involved mediastinal nodes. The maximum SUV of lung tumor correlates strongly with patient outcome. It is the modality of choice for identifying distant metastasis and valuable in locoregional nodal staging for malignant pleural tumors.


Small Cell Lung Carcinoma Carcinoid Tumor Malignant Pleural Mesothelioma Adrenal Metastasis Solitary Pulmonary Nodule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ahuja V, Coleman RE, Herndon J, Patz Jr EF (1998) The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 83:918–924PubMedGoogle Scholar
  2. Al-Sugair A, Coleman RE (1998) Applications of PET in lung cancer. Semin Nucl Med 28:303–319PubMedGoogle Scholar
  3. Antoch G, Stattaus J, Nemat AT et al (2003) Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229:526–533PubMedGoogle Scholar
  4. Arita T, Matsumoto T, Kuramitsu T et al (1996) Is it possible to differentiate malignant mediastinal nodes from benign nodes by size? Reevaluation by CT, transesophageal echocardiography, and nodal specimen. Chest 110:1004–1008PubMedGoogle Scholar
  5. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A (1998) Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 114:713–722PubMedGoogle Scholar
  6. Bille A, Pelosi E, Skanjeti A et al (2009) Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg 36:440–445PubMedGoogle Scholar
  7. Birim O, Kappetein AP, Stijnen T, Bogers AJ (2005) Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 79:375–382PubMedGoogle Scholar
  8. Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA (2004) Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 22:3248–3254PubMedGoogle Scholar
  9. Brady MJ, Thomas J, Wong TZ, Franklin KM, Ho LM, Paulson EK (2009) Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm. Radiology 250:523–530PubMedGoogle Scholar
  10. Brink I, Schumacher T, Mix M et al (2004) Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 31:1614–1620PubMedGoogle Scholar
  11. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P (1998) Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 25:1244–1247PubMedGoogle Scholar
  12. Bury T, Corhay JL, Duysinx B et al (1999) Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 14:1376–1380PubMedGoogle Scholar
  13. Casali C, Cucca M, Rossi G et al (2009) The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma. Lung Cancer 69(2):187–193Google Scholar
  14. Ceresoli GL, Chiti A, Zucali PA et al (2006) Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol 24:4587–4593PubMedGoogle Scholar
  15. Cerfolio RJ, Ojha B, Bryant AS, Bass CS, Bartalucci AA, Mountz JM (2003) The role of FDG-PET scan in staging patients with nonsmall cell carcinoma. Ann Thorac Surg 76:861–866PubMedGoogle Scholar
  16. Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA (2004) The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 78:1017–1023 discussion 1017–1023PubMedGoogle Scholar
  17. Cerfolio RJ, Bryant AS, Ojha B (2006) Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 131:1229–1235PubMedGoogle Scholar
  18. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P (2009) The international association for the study of lung cancer staging project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 4:792–801PubMedGoogle Scholar
  19. Chin R Jr, McCain TW, Miller AA et al (2002) Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 37:1–6PubMedGoogle Scholar
  20. Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR (2007) The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest 131:255–260PubMedGoogle Scholar
  21. Davila DG, Dunn WF, Tazelaar HD, Pairolero PC (1993) Bronchial carcinoid tumors. Mayo Clin Proc 68:795–803PubMedGoogle Scholar
  22. De Leyn P, Stroobants S, De Wever W et al (2006) Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol 24:3333–3339PubMedGoogle Scholar
  23. de Rosado Christenson ML, Abbott GF, Kirejczyk WM, Galvin JR, Travis WD (1999) Thoracic carcinoids: radiologic-pathologic correlation. Radiographics 19:707–736Google Scholar
  24. De Wever W, Ceyssens S, Mortelmans L et al (2007) Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 17:23–32PubMedGoogle Scholar
  25. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG (1995) Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 60:1348–1352PubMedGoogle Scholar
  26. Duysinx B, Nguyen D, Louis R et al (2004) Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest 125:489–493PubMedGoogle Scholar
  27. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL (1999) Metastases from non-small cell lung cancer: mediastinal staging in the 1990 s–meta-analytic comparison of PET and CT. Radiology 213:530–536PubMedGoogle Scholar
  28. Erasmus JJ, Patz EF Jr, McAdams HP et al (1997) Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. Am J Roentgenol 168:1357–1360Google Scholar
  29. Erasmus JJ, McAdams HP, Patz EF Jr, Coleman RE, Ahuja V, Goodman PC (1998) Evaluation of primary pulmonary carcinoid tumors using FDG PET. Am J Roentgenol 170:1369–1373Google Scholar
  30. Erasmus JJ, Truong MT, Smythe WR et al (2005) Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg 129:1364–1370PubMedGoogle Scholar
  31. Eschmann SM, Friedel G, Paulsen F et al (2007) Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 55:165–171PubMedGoogle Scholar
  32. Ettinghausen SE, Burt ME (1991) Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer. J Clin Oncol 9:1462–1466PubMedGoogle Scholar
  33. Fischer B, Lassen U, Mortensen J et al (2009) Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 361:32–39PubMedGoogle Scholar
  34. Fletcher JW, Kymes SM, Gould M et al (2008) A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med 49:179–185PubMedGoogle Scholar
  35. Flores RM, Akhurst T, Gonen M et al (2006) Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 132:763–768PubMedGoogle Scholar
  36. Francis RJ, Byrne MJ, van der Schaaf AA et al (2007) Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 48:1449–1458PubMedGoogle Scholar
  37. Frank A, Lefkowitz D, Jaeger S et al (1995) Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 32:1495–1512PubMedGoogle Scholar
  38. Gerbaudo VH (2003) 18F-FDG imaging of malignant pleural mesothelioma: scientiam impendere vero. Nucl Med Commun 24:609–614PubMedGoogle Scholar
  39. Gerbaudo VH, Britz-Cunningham S, Sugarbaker DJ, Treves ST (2003) Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma. Thorax 58:1077–1082PubMedGoogle Scholar
  40. Goldstraw P, Crowley J, Chansky K et al (2007) The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:706–714PubMedGoogle Scholar
  41. Goudarzi B, Jacene HA, Wahl RL (2008) Diagnosis and differentiation of bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar components with metabolic and anatomic characteristics using PET/CT. J Nucl Med 49:1585–1592PubMedGoogle Scholar
  42. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK (2001) Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285:914–924PubMedGoogle Scholar
  43. Gould MK, Kuschner WG, Rydzak CE et al (2003) Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 139:879–892PubMedGoogle Scholar
  44. Govindan R, Page N, Morgensztern D et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539–4544PubMedGoogle Scholar
  45. Graeter TP, Hellwig D, Hoffmann K, Ukena D, Kirsch CM, Schafers HJ (2003) Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. Ann Thorac Surg 75:231–235 discussion 235–236PubMedGoogle Scholar
  46. Gupta NC, Rogers JS, Graeber GM et al (2002) Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest 122:1918–1924PubMedGoogle Scholar
  47. Gurney JW, Swensen SJ (1995) Solitary pulmonary nodules: determining the likelihood of malignancy with neural network analysis. Radiology 196:823–829PubMedGoogle Scholar
  48. Haberkorn U (2004) Positron emission tomography in the diagnosis of mesothelioma. Lung Cancer 45(Suppl 1):S73–S76PubMedGoogle Scholar
  49. Halpern BS, Schiepers C, Weber WA et al (2005) Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 128:2289–2297PubMedGoogle Scholar
  50. Halter G, Buck AK, Schirrmeister H et al (2004) Lymph node staging in lung cancer using [18F]FDG-PET. Thorac Cardiovasc Surg 52:96–101PubMedGoogle Scholar
  51. Hashimoto Y, Tsujikawa T, Kondo C et al (2006) Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5. J Nucl Med 47:426–431PubMedGoogle Scholar
  52. Hauber HP, Bohuslavizki KH, Lund CH, Fritscher-Ravens A, Meyer A, Pforte A (2001) Positron emission tomography in the staging of small-cell lung cancer : a preliminary study. Chest 119:950–954PubMedGoogle Scholar
  53. Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C (1999) Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. Am J Roentgenol 172:1039–1047Google Scholar
  54. Hellwig D, Groschel A, Graeter TP et al (2006) Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 33:13–21PubMedGoogle Scholar
  55. Heyneman LE, Patz EF (2002) PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer 38:261–266PubMedGoogle Scholar
  56. Hicks RJ, Kalff V, MacManus MP et al (2001a) (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 42:1596–1604PubMedGoogle Scholar
  57. Hicks RJ, Kalff V, MacManus MP et al (2001b) The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 42:1605–1613PubMedGoogle Scholar
  58. Hicks RJ, Mac Manus MP, Matthews JP et al (2004) Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 60:412–418PubMedGoogle Scholar
  59. Higashi K, Clavo AC, Wahl RL (1993) Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 34:414–419PubMedGoogle Scholar
  60. Higashi K, Ueda Y, Seki H et al (1998) Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 39:1016–1020PubMedGoogle Scholar
  61. Higashi K, Ueda Y, Arisaka Y et al (2002) 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 43:39–45PubMedGoogle Scholar
  62. Ho L, Sugarbaker DJ, Skarin AT (2001) Malignant pleural mesothelioma. Cancer Treat Res 105:327–373PubMedGoogle Scholar
  63. Hoekstra CJ, Stroobants SG, Hoekstra OS, Smit EF, Vansteenkiste JF, Lammertsma AA (2002) Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography. Clin Cancer Res 8:2109–2115PubMedGoogle Scholar
  64. Hoekstra CJ, Stroobants SG, Hoekstra OS et al (2003) The value of [18F]fluoro-2-deoxy-d-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer 39:151–157PubMedGoogle Scholar
  65. Hoekstra CJ, Stroobants SG, Smit EF et al (2005) Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23:8362–8370PubMedGoogle Scholar
  66. Inoue T, Kim EE, Komaki R et al (1995) Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 36:788–793PubMedGoogle Scholar
  67. Jemal A, Thun MJ, Ries LA et al (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100:1672–1694PubMedGoogle Scholar
  68. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249PubMedGoogle Scholar
  69. Jeong HJ, Min JJ, Park JM et al (2002) Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 23:865–870PubMedGoogle Scholar
  70. Kamel EM, Zwahlen D, Wyss MT, Stumpe KD, von Schulthess GK, Steinert HC (2003) Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 44:1911–1917PubMedGoogle Scholar
  71. Kerr KM, Lamb D, Wathen CG, Walker WS, Douglas NJ (1992) Pathological assessment of mediastinal lymph nodes in lung cancer: implications for non-invasive mediastinal staging. Thorax 47:337–341PubMedGoogle Scholar
  72. Kim BT, Kim Y, Lee KS et al (1998) Localized form of bronchioloalveolar carcinoma: FDG PET findings. AJR Am J Roentgenol 170:935–939PubMedGoogle Scholar
  73. Kong FM, Frey KA, Quint LE et al (2007) A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol 25:3116–3123PubMedGoogle Scholar
  74. Kramer H, Pieterman RM, Slebos DJ et al (2004) PET for the evaluation of pleural thickening observed on CT. J Nucl Med 45:995–998PubMedGoogle Scholar
  75. Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC (2007) Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 12:1096–1104PubMedGoogle Scholar
  76. Lardinois D, Weder W, Hany TF et al (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500–2507PubMedGoogle Scholar
  77. Lee DH, Kim SK, Lee HY et al (2009a) Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer. J Thorac Oncol 4:816–821PubMedGoogle Scholar
  78. Lee YJ, Cho A, Cho BC et al (2009b) High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res 15:2426–2432PubMedGoogle Scholar
  79. Mac Manus MP, Hicks RJ, Matthews JP et al (2003) Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21:1285–1292PubMedGoogle Scholar
  80. MacManus MP, Hicks RJ, Matthews JP et al (2001) High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 50:287–293PubMedGoogle Scholar
  81. Marom EM, McAdams HP, Erasmus JJ et al (1999) Staging non-small cell lung cancer with whole-body PET. Radiology 212:803–809PubMedGoogle Scholar
  82. Marom EM, Erasmus JJ, Pass HI, Patz EF Jr (2002) The role of imaging in malignant pleural mesothelioma. Semin Oncol 29:26–35PubMedGoogle Scholar
  83. Meyers BF, Haddad F, Siegel BA et al (2006) Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg 131:822–829 discussion 822–829PubMedGoogle Scholar
  84. Nair VS, Barnett PG, Ananth L, Gould MK (2010) PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer. Chest 137:1150–1156PubMedGoogle Scholar
  85. Nakamura H, Taguchi M, Kitamura H, Nishikawa J (2008) Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer. Gen Thorac Cardiovasc Surg 56:404–409PubMedGoogle Scholar
  86. Nestle U, Kremp S, Grosu AL (2006) Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol 81:209–225PubMedGoogle Scholar
  87. Onitilo AA, Engel JM, Demos JM, Mukesh B (2008) Prognostic significance of 18 F-fluorodeoxyglucose—positron emission tomography after treatment in patients with limited stage small cell lung cancer. Clin Med Res 6:72–77PubMedGoogle Scholar
  88. Pandit N, Gonen M, Krug L, Larson SM (2003) Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 30:78–84PubMedGoogle Scholar
  89. Patz EF Jr, Lowe VJ, Hoffman JM et al (1993) Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 188:487–490PubMedGoogle Scholar
  90. Pieterman RM, van Putten JW, Meuzelaar JJ et al (2000) Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343:254–261PubMedGoogle Scholar
  91. Prenzel KL, Monig SP, Sinning JM et al (2003) Lymph node size and metastatic infiltration in non-small cell lung cancer. Chest 123:463–467PubMedGoogle Scholar
  92. Quint LE, Francis IR (1999) Radiologic staging of lung cancer. J Thorac Imaging 14:235–246PubMedGoogle Scholar
  93. Quint LE, Tummala S, Brisson LJ et al (1996) Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg 62:246–250PubMedGoogle Scholar
  94. Rusch VW, Venkatraman E (1996) The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 111:815–825 discussion 825–826PubMedGoogle Scholar
  95. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ (2002) FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 35:179–187PubMedGoogle Scholar
  96. Saunders CA, Dussek JE, O’Doherty MJ, Maisey MN (1999) Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 67:790–797PubMedGoogle Scholar
  97. Schmucking M, Baum RP, Griesinger F et al (2003) Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. Recent Results Cancer Res 162:195–202PubMedGoogle Scholar
  98. Schneider DB, Clary-Macy C, Challa S et al (2000) Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 120:128–133PubMedGoogle Scholar
  99. Schrevens L, Lorent N, Dooms C, Vansteenkiste J (2004) The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist 9:633–643PubMedGoogle Scholar
  100. Schumacher T, Brink I, Mix M et al (2001) FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 28:483–488PubMedGoogle Scholar
  101. Shen YY, Shiau YC, Wang JJ, Ho ST, Kao CH (2002) Whole-body 18F–2-deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res 22:1257–1264PubMedGoogle Scholar
  102. Shepherd FA, Crowley J, Van Houtte P et al (2007) The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2:1067–1077PubMedGoogle Scholar
  103. Steinert HC, Hauser M, Allemann F et al (1997) Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 202:441–446PubMedGoogle Scholar
  104. Subramaniam RM, Wilcox B, Aubry MC, Jett J, Peller PJ (2009) 18F-fluoro-2-deoxy-d-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma. J Med Imaging Radiat Oncol 53:160–169 quiz 170PubMedGoogle Scholar
  105. Sugarbaker DJ, Flores RM, Jaklitsch MT et al (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54–63 discussion 63–65PubMedGoogle Scholar
  106. Swensen SJ, Jett JR, Hartman TE et al (2003) Lung cancer screening with CT: Mayo Clinic experience. Radiology 226:756–761PubMedGoogle Scholar
  107. Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED (2008) US mesothelioma patterns 1973–2002: indicators of change and insights into background rates. Eur J Cancer Prev 17:525–534PubMedGoogle Scholar
  108. Truong MT, Pan T, Erasmus JJ (2006) Pitfalls in integrated CT-PET of the thorax: implications in oncologic imaging. J Thorac Imaging 21:111–122PubMedGoogle Scholar
  109. van Tinteren H, Hoekstra OS, Smit EF et al (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359:1388–1393PubMedGoogle Scholar
  110. Vansteenkiste JF, Stroobants SG, De Leyn PR et al (1997) Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group. Chest 112:1480–1486PubMedGoogle Scholar
  111. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verbeken EK (1998) Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol 9:1193–1198PubMedGoogle Scholar
  112. Vansteenkiste JF, Stroobants SG, Dupont PJ et al (1999) Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17:3201–3206PubMedGoogle Scholar
  113. Vinjamuri M, Craig M, Campbell-Fontaine A, Almubarak M, Gupta N, Rogers JS (2008) Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer 9:30–34PubMedGoogle Scholar
  114. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150SPubMedGoogle Scholar
  115. Weber WA, Petersen V, Schmidt B et al (2003) Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21:2651–2657PubMedGoogle Scholar
  116. Yang W, Fu Z, Yu J et al (2008) Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. Lung Cancer 61:35–43PubMedGoogle Scholar
  117. Yildirim H, Metintas M, Entok E et al (2009) Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J Thorac Oncol 4:1480–1484PubMedGoogle Scholar
  118. Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773–1782PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Rathan M. Subramaniam
    • 4
    • 1
  • J. M. Davison
    • 1
  • D. S. Surasi
    • 1
  • Gregory Russo
    • 3
  • P. J. Peller
    • 2
  1. 1.Boston University School of MedicineBostonUSA
  2. 2.Department of RadiologyMayo Clinic College of MedicineRochesterUSA
  3. 3.Department of Radiation OncologyBoston University School of MedicineBostonUSA
  4. 4.Russell H Morgan Department of Radiology and Radiological Sciences InstitutionsThe Johns Hopkins Medical InstitutionsBaltimore USA

Personalised recommendations